Company performance
Add to research
Current Price
as of May 23, 2025$13.42
P/E Ratio
N/A
Market Cap
$1.95B
Description
Add to research
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Metrics
Add to research
Overview
- HQSan Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerDNLI
- Price$13.42-1.76%
Trading Information
- Market cap$1.95B
- Float86.58%
- Average Daily Volume (1m)1,261,667
- Average Daily Volume (3m)1,444,787
- EPS-$2.67
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$132.97M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$143.26M
- EV$1.56B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B1.74
- Debt/Equity4.33
Documents
Add to research
SEC Filings
Factset Street Account
Factset